We have also proposed to combine Didymin with PD-L1 mAbs due to implications between RKIP and PD-L1 through EMT factors, GSK3β signaling, and N-MYC in treatments of neuroblastoma. The gene discussed is MYCN; the disease is neuroblastoma.